Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

COSCIENS Biopharma Inc T.AEZS

COSCIENS Biopharma Inc., formerly Aeterna Zentaris Inc., is a specialty biopharmaceutical company engaged in the development and commercialization of a diverse portfolio of pharmaceutical and diagnostic products, including those focused on areas of unmet medical need. Its lead product, macimorelin (Macrilen; Ghryvelin), is an oral test indicated for the diagnosis of adult growth hormone deficiency (AGHD). The Company is also engaged in the development of therapeutic assets and proprietary extraction technology, which is applied to the production of active ingredients from renewable plant resources used in cosmeceutical products (i.e., oat beta glucan and avenanthramides, which are found in skincare product brands like Aveeno and Burt’s Bees formulations) and being developed as potential nutraceuticals and/or pharmaceuticals.


TSX:AEZS - Post by User

Comment by Ciaoon Jul 16, 2024 4:27pm
108 Views
Post# 36135513

RE:RE:New Press Release - Aeterna Zentaris Announces Results of Virtual 2024 Meeting of Shareholders

RE:RE:New Press Release - Aeterna Zentaris Announces Results of Virtual 2024 Meeting of Shareholders
Ciao wrote: Explanation for the recent runup in the share price.

They can see the votes in advance of the AGM so it became clear that Gilles needed some help in the amount of about 20K shares. So just prior to the meeting, we saw a runup in the share price due to poor liquidity as 20K friendly shares were effectively bought at market.

Oats, unfortunately not enough and too late. Never give management the benefit of the doubt or unending trust. When he suggested that you not partake in conversations with others leading up to the merger approval, that was a clear sign that he wanted you to see only his narrative.


My error, technically one had to be owners of shares with a record date of June 14th to vote, so the runup was for another reason as others thought, just to buy YES votes based on short term share price performance leading up to the AGM.
<< Previous
Bullboard Posts
Next >>